Score Overview
Explore the 2021 public Archive ranking →
Where XTL Biopharmaceuticals Ltd ADR has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 20 years of fundamentals. XTLB does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 2.21 | — |
1 Year2025-09-29 | $ 4.84 | -54.34% |
5 Years2021-09-29 | $ 16.68 | -86.75% |
10 Years2016-09-29 | $ 18.82 | -88.26% |
20 Years2006-09-29 | $ 462.00 | -99.52% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 |
|---|---|---|---|---|---|
| Price | $ 2.21 | $ 4.84 | $ 16.68 | $ 18.82 | $ 462.00 |
| Return | — | -54.34% | -86.75% | -88.26% | -99.52% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 289K | -$ 255K | $ 144K |
| 2025 | $ 0.00 | -$ 6M | $ 144K |
| 2024 | $ 451K | -$ 1M | $ 1M |
| 2023 | $ 0.00 | $ 2M | |
| 2022 | -$ 459K | -$ 1M | $ 3M |
| 2021 | $ 1M | $ 435K | $ 6M |
| 2020 | $ 28K | -$ 782K | $ 6M |
| 2019 | $ 69K | -$ 1M | $ 6M |
| 2018 | $ 52K | $ 2M | $ 8M |
| 2017 | $ 29K | -$ 781K | $ 6M |
| 2016 | $ 23K | -$ 2M | $ 2M |
| 2015 | -$ 6K | -$ 4M | $ 4M |
| 2014 | $ 41K | -$ 2M | $ 2M |
| 2013 | $ 2M | -$ 2M | $ 4M |
| 2012 | $ 938K | -$ 1M | $ 3M |
| 2011 | -$ 1M | $ 1M | |
| 2010 | -$ 1M | $ 1M | |
| 2009 | $ 2M | $ 412K | |
| 2008 | $ 5M | -$ 9M | $ 2M |
| 2007 | $ 907K | -$ 24M | $ 12M |
| 2006 | $ 454K | -$ 15M | $ 25M |
| IPO2005 | $ 3M | -$ 14M | $ 13M |
XTL Biopharmaceuticals Ltd ADR fundamental performance
Between 2015 and 2025, revenue went from -$ 6K to $ 0.00 and net income went from -$ 4M to -$ 6M. Revenue increased in 7 of those 10 years; net income in 6.
Across XTL Biopharmaceuticals Ltd ADR's full reported history, from 2005 to 2025, revenue declined from $ 3M to $ 0.00 and net income went from -$ 14M to -$ 6M. Revenue increased in 65% of the years measured; net income in 47%.
XTL Biopharmaceuticals Ltd ADR currently holds a 20-year HDB Score of 3.1 out of 10. How the HDB Score is calculated.
Membership
Explore XTLB with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
